Camp4 Therapeutics (CAMP) Net Equity Issued and Repurchased (2023 - 2024)
Camp4 Therapeutics (CAMP) posted Net Equity Issued and Repurchased of $76.3 million for Q4 2024, up 246093.55% sequentially from $31000.0 in Q3 2024, and up 636100.0% YoY from N/an in Q1 2024.
Powered by 
Analysis
Camp4 Therapeutics (CAMP) Net Equity Issued and Repurchased (2023 - 2024) Analysis & Trends
Camp4 Therapeutics has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $76.3 million in Q4 2024.
- Quarterly Net Equity Issued and Repurchased rose 636100.0% year-over-year to $76.3 million in Q4 2024, while the trailing twelve-month figure through Jun 2025 was $76.4 million (changed N/A YoY) and the FY2025 annual result came in at $57.5 million, down 24.67% from the prior year.
- Net Equity Issued and Repurchased improved to $76.3 million in Q4 2024 per CAMP's latest filing, from $31000.0 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $76.3 million in Q4 2024 and troughed at -$12000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Camp4 Therapeutics | 260.10 Mn | 260.10 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 76.32 Mn |
| Sep 30, 2024 | 31,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | -12,000.00 |